奈达铂联合替加氟治疗中晚期食管癌的临床观察

Clinical observation of nedaplatin combined with tegafur in the treatment of middle and advanced esophageal cancer

目的观察奈达铂联合替加氟治疗中晚期食管癌的治疗效果及不良反应。方法选取2008年1月至2011年1月间收治的64例中晚期食管癌患者,按照随机数字表法分为观察组和对照组,每组各32例。观察组患者采用奈达铂联合替加氟方案治疗,对照组患者采用顺铂联合氟尿嘧啶方案治疗。比较两组患者的疗效和不良反应。结果观察组患者近期总有效率为56.3%,高于对照组的34.4%,差异有统计学意义(P<0.05)。观察组和对照组患者的中位无进展生存期分别为8.5和5.6个月,差异有统计学意义(P<0.05)。观察组患者的中位生存期为17.5个月,高于对照组的11.5个月,差异有统计学意义(P<0.05)。观察组患者恶心、呕吐发生率和肾功损害发生率分别为25.0%和6.3%,明显低于对照组的56.3%和31.3%,差异均有统计学意义(均P<0.05)。结论奈达铂联合替加氟方案治疗中晚期食管癌优于顺铂联合氟尿嘧啶方案,可提高患者的生存率,降低不良反应,值得临床推广。

Objective To observe the therapeutic efficacy and side effects of nedaplatin and tegafur in the treatment of middle and advanced esophageal cancer. Methods From January 2008 to January 2011 in 521 Hospital of China North Industries Group,64 patients with middle and advanced esophageal cancer were enrolled in the study and randomly divided into the observation group and the control group,32 cases in each group. The patients in the observation group accepted nedaplatin and tegafur regimen and the patients in the control group accepted cis-platinum and fluorouracil regimen. The therapeutic effects and side effects were observed and compared. Results The total effective rate of the observation group（ 56. 3%）was higher than that of the control group（ 34. 4%）,with significant difference（ P 〈 0. 05）. The median progression free survival（ PFS） in the observation group and the control group were 8. 5 mo and 5. 6 mo,respectively,with significant difference（ P 〈 0. 05）. The median overall survivals（ OS） in the observation group was 17. 5 mo,which was longer than that of the control group（ 11. 5 mo）,with significant difference（ P 〈 0. 05）. The rate for nausea and vomiting in the observation group was 25. 0%,which was obviously lower than 56. 3% in the control group（ P 〈 0. 05）. The renal damage incidence rate in the observation group was 6. 3%,which was also lower than 31. 3% in the control group（ P 〈 0. 05）. Conclusions Nedaplatin and tegafur in the treatment of middle and advanced esophageal cancers is better than cis-platinum and fluorouracil. It can increase the survival rate and decrease the toxic and side reaction.